Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer

Pancreatic cancer (PC) is one of the most aggressive types of cancer, with a five-year overall survival rate of 11% among all-comers. Current systemic therapeutic options are limited to cytotoxic chemotherapies which have limited clinical efficacy and are often associated with development of drug re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zarei, Mehrdad, Hajihassani, Omid, Hue, Jonathan J., Graor, Hallie J., Rothermel, Luke D., Winter, Jordan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081181/
https://www.ncbi.nlm.nih.gov/pubmed/37034685
http://dx.doi.org/10.1101/2023.03.29.534596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081181/
https://www.ncbi.nlm.nih.gov/pubmed/37034685
http://dx.doi.org/10.1101/2023.03.29.534596

Ejemplares similares